Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
50 participants
INTERVENTIONAL
2025-11-30
2026-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GA patients
Anterior chamber paracentesis (ACP)
AC Tap (anterior chamber paracenthesis)
anterior chamber paracenthesis (microvolume of eye fluid is taken)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AC Tap (anterior chamber paracenthesis)
anterior chamber paracenthesis (microvolume of eye fluid is taken)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For the GA cohort: Clinical diagnosis of GA secondary to AMD or dAMD in the study eye, confirmed by fundus autofluorescence imaging and spectral-domain optical coherence tomography (SD-OCT).
* For the control cohort: No clinical evidence of retinal disease in either eye.
* Best-corrected visual acuity (BCVA) of ≥20/200 in the study eye, as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) charts
* Ability and willingness to provide written informed consent before any study-specific procedures.
Exclusion Criteria
* History of intraocular surgery in the study eye within the three months preceding enrollment.
* Intraocular pressure (IOP) greater than 21 mmHg in the study eye at screening
* Use of systemic anticoagulation therapy that cannot be safely discontinued prior to ACP.
* Pregnant or nursing women.
* Known hypersensitivity or contraindication to any of the medications or procedures used in the study.
50 Years
89 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ClinOmicsAI
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Erie Retina Research
Erie, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Bethany Scott
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COAI-OPTICA-001
Identifier Type: -
Identifier Source: org_study_id